Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma  

作　　者：Liia Akhuba Zhanna Tigai Dmitrii Shek 

机构地区：[1]School of Health Sciences,Western Sydney University,Sydney,NSW 2145,Australia [2]Accreditation Centre,RUDN University,Moscow 117198,Russia [3]Blacktown Clinical School,Western Sydney University,Sydney,NSW 2145,Australia [4]Blacktown Mt Druitt Hospital,Sydney,NSW 2145,Australia [5]Westmead Institute for Medical Research,Sydney,NSW 2145,Australia

出　　处：《Cancer Drug Resistance》2023年第2期327-331,共5页癌症耐药（英文）

摘　　要：In 2030,pancreatic ductal adenocarcinoma(PDAC)will become the second leading cause of cancer-related mortality in the world.Unfortunately,neither conventional chemotherapy nor novel immunotherapeutic strategies can provide durable responses and the survival prognosis remains very low.PDAC is notorious for its immuneresistant features and unique genomic landscape facilitating tumor escape from immunosurveillance.Novel immune-checkpoint inhibitors(ICI)failed to show promising efficacy and other multi-modal approaches are currently being validated in multiple clinical trials.In this paper,we provide our opinion on the major mechanisms responsible for PDAC resistance to ICI therapy and provide our view on future strategies which may overcome those barriers.

关 键 词：Pancreatic cancer immune-checkpoint inhibitors tumor resistance MICROENVIRONMENT 

分 类 号：R735.9[医药卫生—肿瘤]